{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:28:00Z","timestamp":1785871680725,"version":"3.56.0"},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,11,6]]},"DOI":"10.1248\/bpb.b25-00058","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T22:06:21Z","timestamp":1762380381000},"page":"1715-1720","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the Risk of Paradoxical Psoriasis between Monoclonal Antibody and Non-monoclonal Antibody Tumor Necrosis Factor-&lt;i&gt;\u03b1&lt;\/i&gt; Inhibitors in Patients with Rheumatoid Arthritis: An Observational Study Using a Claims Database"],"prefix":"10.1248","volume":"48","author":[{"given":"Minoru","family":"Shimazaki","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Integrated Health Sciences, Faculty of Medicine, The University of Tokyo, 7\u20133\u20131 Hongo, Bunkyo-ku, Tokyo 113\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7\u20133\u20131 Hongo, Bunkyo-ku, Tokyo 113\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koide","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7\u20133\u20131 Hongo, Bunkyo-ku, Tokyo 113\u20138655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Croft M, Salek-Ardakani S, Ware CF. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. <i>Nat. Rev. Drug Discov.<\/i>, <b>23<\/b>, 939\u2013961 (2024).","DOI":"10.1038\/s41573-024-01053-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, Lapointe AK, French LE, Vernez M, Gilliet M. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. <i>Nat. Commun.<\/i>, <b>9<\/b>, 25 (2018).","DOI":"10.1038\/s41467-017-02466-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. <i>Rheumatol. Int.<\/i>, <b>42<\/b>, 1493\u20131511 (2022).","DOI":"10.1007\/s00296-022-05136-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. <i>J. Am. Acad. Dermatol.<\/i>, <b>86<\/b>, 1080\u20131091 (2022).","DOI":"10.1016\/j.jaad.2020.12.010"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Xie W, Xiao S, Huang H, Zhang Z. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. <i>Front. Immunol.<\/i>, <b>13<\/b>, 847160 (2022).","DOI":"10.3389\/fimmu.2022.847160"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Baganz L, Listing J, Kekow J, Eisterhues C, Wassenberg S, Zink A, Strangfeld A. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. <i>Semin. Arthritis Rheum.<\/i>, <b>50<\/b>, 36\u201341 (2020).","DOI":"10.1016\/j.semarthrit.2019.07.004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hern\u00e1ndez MV, Sanmart\u00ed R, Ca\u00f1ete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. <i>Arthritis Care Res. (Hoboken)<\/i>, <b>65<\/b>, 2024\u20132031 (2013).","DOI":"10.1002\/acr.22096"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. <i>Ann. Rheum. Dis.<\/i>, <b>68<\/b>, 209\u2013215 (2009).","DOI":"10.1136\/ard.2007.087288"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Joulfayan H, Makunts T, Abagyan R. Anti-TNF-\u03b1 therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data. <i>Sci. Rep.<\/i>, <b>13<\/b>, 10448 (2023).","DOI":"10.1038\/s41598-023-37010-6"},{"key":"10","unstructured":"10) Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. <i>Clin. Exp. Rheumatol.<\/i>, <b>20<\/b> (Suppl. 28), S34\u2013S37 (2002)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ho CH, Silva AA, Tomita B, Weng HY, Ho IC. Differential impacts of TNF\u03b1 inhibitors on the transcriptome of Th cells. <i>Arthritis Res. Ther.<\/i>, <b>23<\/b>, 199 (2021).","DOI":"10.1186\/s13075-021-02558-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims database sourced from health insurance societies. <i>J. Gen. Fam. Med.<\/i>, <b>22<\/b>, 118\u2013127 (2021).","DOI":"10.1002\/jgf2.422"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tada Y, Soliman AM, Ishii K, Sakuma R, Puig L, Davis M, Nunag D, Pinter A, Imafuku S. Real-world discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan. <i>Dermatol. Ther. (Heidelb.)<\/i>, <b>14<\/b>, 99\u2013114 (2024).","DOI":"10.1007\/s13555-023-01064-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tada Y, Kim H, Spanopoulos D, Habiro K, Tsuritani K, Yamada Y, Mandal A, Zhong Y, Hikichi Y. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. <i>J. Dermatol.<\/i>, <b>49<\/b>, 1106\u20131117 (2022).","DOI":"10.1111\/1346-8138.16543"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Miyazaki C, Masuda J, Rodriguez-Rey MD, Stelmaszuk MN, Freilich J, Tsai PI, Saeki H. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan. <i>J. Dermatolog. Treat.<\/i>, <b>35<\/b>, 2299598 (2024).","DOI":"10.1080\/09546634.2023.2299598"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Toussirot \u00c9., Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. <i>RMD Open<\/i>, <b>2<\/b>, e000239 (2016).","DOI":"10.1136\/rmdopen-2015-000239"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. <i>J. Clin. Epidemiol.<\/i>, <b>48<\/b>, 1503\u20131510 (1995).","DOI":"10.1016\/0895-4356(95)00048-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) St\u00fcrmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. <i>J. Intern. Med.<\/i>, <b>275<\/b>, 570\u2013580 (2014).","DOI":"10.1111\/joim.12197"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, Jager KJ. An introduction to inverse probability of treatment weighting in observational research. <i>Clin. Kidney J.<\/i>, <b>15<\/b>, 14\u201320 (2022).","DOI":"10.1093\/ckj\/sfab158"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. <i>Stat. Med.<\/i>, <b>33<\/b>, 1242\u20131258 (2014).","DOI":"10.1002\/sim.5984"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Smolen JS, Landew\u00e9 RBM, Bergstra SA, <i>et al.<\/i> EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. <i>Ann. Rheum. Dis.<\/i>, <b>82<\/b>, 3\u201318 (2023).","DOI":"10.1136\/ard-2022-223356corr1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Costin D, Burlui AM, Cardoneanu A, Macovei LA, Rezus C, Bratoiu I, Richter P, Mihai IR, Gherasim A, Danielescu C, Rezus E. Paradoxical psoriasis in patients receiving therapy with tumor necrosis factor inhibitors: potential pathogenic mechanisms and the role of genetic factors. <i>Int. J. Mol. Sci.<\/i>, <b>25<\/b>, 7018 (2024).","DOI":"10.3390\/ijms25137018"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Hern\u00e1n MA. Causal analyses of existing databases: no power calculations required. <i>J. Clin. Epidemiol.<\/i>, <b>144<\/b>, 203\u2013205 (2022).","DOI":"10.1016\/j.jclinepi.2021.08.028"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00058\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:23:30Z","timestamp":1762572210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00058\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00058","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"b25-00058"}}